NEO 100 Enables Noninvasive, Therapeutically Effective Delivery of Pharmaceutical Agents
March 28, 2019
Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models
Authors: Weijun Wang, MD1, Steve Swenson, PhD1, Hee-Yeon Cho, PhD1, Florence M. Hofman, PhD2, Axel H. Schönthal, PhD3, and Thomas C. Chen, MD, PhD1,2
This study demonstrates that intranasal delivery with a NEO100-based formulation enables noninvasive, therapeutically effective brain delivery of a pharmaceutical agent that otherwise does not efficiently cross the BBB.
1 Departments of Neurosurgery, 2 Department of Pathology, 3 Molecular Microbiology & Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California